We therefore explored whether tucidinostat could alter the antigen-presenting function of monocytes (CD14+CD11b+) among the peripheral blood mononuclear cells (PBMCs) of patients with non-small cell lung cancer (NSCLC). This evidence concerns the gene ITGAM and non-small cell lung carcinoma.